

◆ Department of Continuing Medical Education ◆

Conflict of Interest Disclosure and Resolution & Core Competencies
CCG Course | Intensive Course in Community Cancer Genetics and Research Training
Distance Learning Only (Track 2)
October 29, 2021– March 25, 2022

CONFLICT OF INTEREST DISCLOSURE AND RESOLUTION

City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME). As a fully accredited ACCME Category 1 CME credit provider, the Continuing Medical Education Department has in place policies and procedures which insure the balance, independence, objectivity and scientific rigor in all of its educational activities. City of Hope complies with the [Standards for Integrity and Independence in Accredited Continuing Education](#) of the (ACCME), which REQUIRE that all relevant disclosed conflicts of interest be mitigated prior to the educational activity.

To this end all faculty presenters who are in a position to control the content of an educational activity must identify any real or apparent conflict(s) of interest by disclosing to the Department of CME all relevant financial relationships¹ with any ineligible company². To comply with more intense scrutiny by accreditation agencies, should you disclose any relevant conflict of interest with an ineligible company, the content of your presentation must be peer reviewed prior to presenting. Presentations will be provided to participants as an e-syllabus or in a meeting handout, all relevant disclosures will be made known to participants prior to the start of the activity.

In furtherance of program impartiality, we request the use of generic drug names in your presentation as opposed to trade names. Under no circumstances will we accept trade names. Additionally, contents of your presentation must be based solely on scientific methods generally accepted by the medical community. Data will have been objectively selected from peer-reviewed literature and will be presented in an unbiased manner.

CORE COMPETENCIES

The American Board of Medical Specialties (ABMS) and the Accreditation Council of Graduate Medical Education (ACGME) have embarked on a joint initiative to quantify and evaluate a set of 6 physician core competencies by which the individual physician will be measured for Residency Certification, Board Certification and more recently, Maintenance of Certification (MOC). Individual hospitals and other health care delivery organizations will now also be evaluated by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) on their practice and demonstration of the 6 core competencies.

In brief, the actual term “core competencies” refers to those six abilities (competencies) that are central (core) to the practice of medicine, specifically: (1) Patient Care, (2) Medical Knowledge, (3) Practice-Based Learning and Improvement, (4) Interpersonal and Communication Skills, (5) Professionalism and (6) Systems-Based Practice. To assist our conferees in demonstrating their completion of CME in the six core competencies, the educational content of each presentation will be noted by numbers 1-6 in the table below. CME certificates for this activity will reflect those core competencies addressed by the educational content of the overall conference.

Conference Faculty	Commercial Interest	Conflict/Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Jasmine Alcantara, BS	I do not have any relevant financial relationships with any ineligible companies.	None	None
Kathleen R. Blazer, EdD, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3 & 4
Danielle Castillo, BS	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 3
Jane E. Churpek, MD, MS	Other financial interest in UptoDate, Inc.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 2
Julie Culver, MS, LCGC, CCRP	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Sandra Dreike, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 6
Tobias Else, MD	Grant/Research Support from Department of Defense, and National Institute of Health; Consultant for Corcept Therapeutics, HRA Pharma, and Merck.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 5 & 6
Deanna Erwin, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1 & 2

Conference Faculty	Commercial Interest	Conflict/Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Carol J. Fabian, MD, FASCO	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Conjugated estrogens/bazedoxifene</i>	1, 2, 3 & 4
Judy E. Garber, MD, MPH	Grant/Research Support from Amby Genetics, AstraZeneca, Invitae Genetics, and Myriad Genetics; Consultant (Self) for Helix Genetics, and Konica Minolta, (Spouse): Aleta Biotherapeutics, GTx, Inc., GV20 Therapeutics, H3 Biomedicine, Inc., Kronos Bio, and Novartis Oncology.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted. <i>Off-label/Investigational use of: Denosumab</i>	1, 2, 3, 4, 5 & 6
Lauren Gima, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	2 & 3
Veda N. Giri, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Stacy W. Gray, MD, AM	Consultant for Triptych Health Partners (Self) and Magenta Therapeutics (Spouse).	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 6
Heather Hampel, MS, LGC	Consultant for Genome Medical, Invitae Genetics, and Promega; Stock/Shareholder in Genome Medical, and GI on Demand.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 6
Karen E. Hurley, PhD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 4 & 5
Gregory Idos MD, MS	Grant/Research Support from Myriad Genetics.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1 & 2
Sonia S. Kupfer, MD	I do not have any relevant financial relationships with any ineligible companies.	None <i>Off-label/Investigational use of: Aspirin</i>	1, 2, 3, 4, 5 & 6
Daneng Li, MD	I do not have any relevant financial relationships with any ineligible companies.	None	Reviewer
Patrick M. Lynch, JD, MD	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Rachelle Manookian, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	2, 3 & 6
Bitu Nehoray, MS, CGC	Consultant for Invitae.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, 5 & 6
Wai Park, DO	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Colin C. Pritchard MD, PhD	Consultant for AstraZeneca.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 5 & 6
Padma Sheila Rajagopal, MD, MPH, MSc	I do not have any relevant financial relationships with any ineligible companies.	None	2

Conference Faculty	Commercial Interest	Conflict/Resolution & Faculty Discussion of Off-Label Drugs	Core Competencies
Charité Ricker, MS, LCGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2, 3, 4, 5 & 6
Suzie Shehayeb, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None	1, 2 & 3
Brian Shuch, MD	Consultant for Genentech, Johnson & Johnson, Histosonics, Merck, and Veracyte.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3 & 6
Ilana Solomon, ScM, MA	I do not have any relevant financial relationships with any ineligible companies.	None	1, 3, 4 & 6
Jeffrey N. Weitzel, MD	On the Speakers Bureau for AstraZeneca.	The educational content has been peer-reviewed, an attestation on file and no conflicts were noted.	1, 2, 3, 4, & 5

Planning Committee	Commercial Interest	Conflict/Resolution
Kathleen R. Blazer, EdD, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Alexandra Capasso, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Sandra Dreike, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Lauren Gima, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Joseph Herzog, BS	I do not have any relevant financial relationships with any ineligible companies.	None
Elisabeth King, FNP, AOCNP, AGN	I do not have any relevant financial relationships with any ineligible companies.	None
Phyllis Leung, MPH	I do not have any relevant financial relationships with any ineligible companies.	None
John Luna, BS, MS	I do not have any relevant financial relationships with any ineligible companies.	None
Rachelle Manookian, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Bitia Nehoray, MS, CGC	Consultant for Invitae Corporation.	Attestation on file – No conflict noted
Gloria Nunez, MPH	I do not have any relevant financial relationships with any ineligible companies.	None
Suzie Shehayeb, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Elise Sobotka, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None
Dev Tanna, BS	I do not have any relevant financial relationships with any ineligible companies.	None
Kevin Tsang, BS	I do not have any relevant financial relationships with any ineligible companies.	None

Planning Committee	Commercial Interest	Conflict/Resolution
Elyssa Zukin, MS, CGC	I do not have any relevant financial relationships with any ineligible companies.	None

1. The ACCME defines “relevant” financial relationships” as financial relationships with an ineligible company (in any amount), occurring within the past 24 months, that create a conflict of interest.
2. The ACCME defines an “Ineligible company” as any entity producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.